Skip to main content
. 2023 Dec 8;12(24):21920–21932. doi: 10.1002/cam4.6766

FIGURE 4.

FIGURE 4

Overall survival of patients with progression. Overall survival (OS) of patients who received targeted therapy or not among patients with progression (A, B), patients with progression and harboring TP53 mutations (C), patients with progression and harboring WT TP53 (D), patients with progression and harboring TP53 GOF mutations (E) or non‐GOF mutations (F), patients with progression and harboring TP53 known LOF mutations (G) or likely LOF mutations (H).